MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Neurocrine Biosciences Inc

Затворен

СекторЗдравеопазване

108.28 1.21

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

105.31

Максимум

108.39

Ключови измерители

By Trading Economics

Приходи

-27M

103M

Продажби

5.6M

628M

P/E

Средно за сектора

33.617

63.778

EPS

1.69

Марж на печалбата

16.425

Служители

1,800

EBITDA

-39M

152M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+53.74% upside

Дивиденти

By Dow Jones

Следващи печалби

30.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-3.8B

11B

Предишно отваряне

107.07

Предишно затваряне

108.28

Настроения в новините

By Acuity

50%

50%

180 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Neurocrine Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.01.2025 г., 00:03 ч. UTC

Горещи акции

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

14.03.2025 г., 09:30 ч. UTC

Топ новини

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

13.08.2024 г., 11:30 ч. UTC

Топ новини

S&P 500 Futures Climb In Premarket Trading; On Holding, Western Midstream Ptrs Lag

Сравнение с други в отрасъла

Ценова промяна

Neurocrine Biosciences Inc Прогноза

Ценова цел

By TipRanks

53.74% нагоре

12-месечна прогноза

Среден 164.5 USD  53.74%

Висок 192 USD

Нисък 138 USD

Според 22 анализатори от Wall Street, предложили 12-месечна ценова цел за Neurocrine Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

22 ratings

17

Купи

5

Задържане

0

Продай

Техническа оценка

By Trading Central

106.49 / 110.685Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

180 / 386 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.